Publications by authors named "Robin Carson"

Claim this Profile
S
Subcutaneous daratumumab plus carfilzomib and dexamethasone (D-Kd) versus carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma who received previous daratumumab treatment: LYNX study.
Nizar J Bahlis, Jeffrey Zonder, Lionel Karlin, Torben Plesner, Laura Paris, Robin Carson

Leuk Lymphoma· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes in patients with relapsed/refractory multiple myeloma with extramedullary disease: a meta-analysis.
Peter M Voorhees, Shaji Kumar, Saad Z Usmani, Jing Christine Ye, Yael C Cohen, Robin L Carson

Ann Hematol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma.
Luciano J Costa, Nizar J Bahlis, Aurore Perrot, Ajay K Nooka, Jin Lu, Robin Carson

N Engl J Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating tumor cells in myeloma are a compound biomarker for bone marrow high-risk genomic alterations and tumor load.
Cathelijne Fokkema, Luca Bertamini, Madelon M E de Jong, Sabrin Tahri, Davine Hofste Op Bruinink, Robin Carson

Blood· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab for newly diagnosed multiple myeloma: Pooled analysis of patients aged ≥65 years from GRIFFIN and PERSEUS.
Paula Rodriguez-Otero, Peter M Voorhees, Mario Boccadoro, Jacob Laubach, Hermann Einsele, Robin Carson

Clin Lymphoma Myeloma Leuk· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses.
Laahn Foster, Larry D Anderson, Alfred Chung, Chakra P Chaulagain, Erin Pettijohn, Robin Carson

Blood Cancer J· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A plain language summary of the CEPHEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for people with newly diagnosed multiple myeloma who are not expected to receive a stem cell transplant.
Saad Z Usmani, Thierry Facon, Vania Hungria, Nizar J Bahlis, Christopher P Venner, Robin Carson

Future Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone.
Luca Bertamini, Cathelijne Fokkema, Paula Rodriguez-Otero, Mark van Duin, Evangelos Terpos, Robin Carson

Blood· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results.
Jill Corre, Laure Vincent, Philippe Moreau, Benjamin Hebraud, Cyrille Hulin, Robin Carson

Blood· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma.
Meletios A Dimopoulos, Peter M Voorhees, Fredrik Schjesvold, Yael C Cohen, Vania Hungria, Robin Carson

N Engl J Med· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone: MAIA Final Analysis of Patient-Reported Outcomes.
Aurore Perrot, Thierry Facon, Torben Plesner, Saad Z Usmani, Shaji Kumar, Robin Carson

Eur J Haematol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial.
Maria-Victoria Mateos, Jesus San-Miguel, Michele Cavo, Kenshi Suzuki, Andrzej Jakubowiak, Robin Carson

Lancet Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world data on the use of subcutaneous daratumumab plus bortezomib, thalidomide, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma.
Vania Hungria, Fernanda Lemos Moura, Abel Costa, Eduardo Flávio Oliveira Ribeiro, Paulo Soares, Robin Carson

Ann Hematol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life with daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible patients with newly diagnosed multiple myeloma: analysis of the phase 3 OCTANS study.
Weijun Fu, Soo-Mee Bang, Honghui Huang, Kihyun Kim, Wei Li, Robin Carson

Ann Hematol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of daratumumab in intermediate/high-risk smoldering multiple myeloma: final analysis of CENTAURUS.
Ola Landgren, Ajai Chari, Yael C Cohen, Andrew Spencer, Peter M Voorhees, Robin Carson

Blood· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial.
Saad Z Usmani, Thierry Facon, Vania Hungria, Nizar J Bahlis, Christopher P Venner, Robin Carson

Nat Med· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial.
Saad Z Usmani, Thierry Facon, Vania Hungria, Nizar J Bahlis, Christopher P Venner, Robin Carson

Nat Med· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes.
Thierry Facon, Philippe Moreau, Katja Weisel, Hartmut Goldschmidt, Saad Z Usmani, Robin Carson

Leukemia· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study.
Philippe Moreau, Thierry Facon, Saad Z Usmani, Nizar Bahlis, Noopur Raje, Robin Carson

Leukemia· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study.
Weijun Fu, Soo-Mee Bang, Honghui Huang, Kihyun Kim, Wei Li, Robin Carson

Ann Hematol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study.
Ashraf Badros, Laahn Foster, Larry D Anderson, Chakra P Chaulagain, Erin Pettijohn, Robin Carson

Blood· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characteristics and outcomes in patients with lenalidomide-refractory multiple myeloma treated with 1-3 prior lines of therapy: Analysis of individual patient-level data from daratumumab clinical trials.
Kwee Yong, Hermann Einsele, Jordan M Schecter, Tito Roccia, William Deraedt, Robin Carson

Eur J Cancer· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world characteristics and outcomes of patients with high-risk and non-high-risk smoldering multiple myeloma using the Flatiron Health database.
S Vincent Rajkumar, María-Victoria Mateos, Marcy Schaeffer, Xiwu Lin, Sacheeta Bathija, Robin Carson

Blood Cancer J· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myeloma.
Pieter Sonneveld, Meletios A Dimopoulos, Mario Boccadoro, Hang Quach, P Joy Ho, Robin Carson

Future Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS study.
Weijun Fu, Soo-Mee Bang, Honghui Huang, Kihyun Kim, Wei Li, Robin Carson

Ann Hematol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis